By manufacturing a single-particle system in two particulate forms (ie, micrometer size and
nanometer size), we have designed a bacterial vaccine form that exhibits improved efficacy of …

Antigen-specific, MHC-restricted αβ T cells are necessary for protective immunity against
Mycobacterium tuberculosis, but the ability to broadly study these responses has been limited. …

Background Despite the high disease burden of respiratory syncytial virus (RSV) in older
adults, there is no approved vaccine. We evaluated the experimental RSV vaccine, Ad26.RSV.…

Respiratory syncytial virus (RSV) infection is a major cause of severe lower respiratory tract
infection and death in young infants and the elderly. With no effective prophylactic treatment …

With the increasing incidence of tuberculosis and drug resistant disease in developing
countries due to HIV/AIDS, there is a need for vaccines that are more effective than the present …

Background: A prophylactic HIV-1 vaccine is a global health priority. Objective: To assess a
novel vaccine platform as a prophylactic HIV-1 regimen. Design: Randomized, double-blind, …

It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV)
vaccines. In the absence of efficacy data, immunobridging is an approach to infer the …

Background BCG vaccination, combined with adenoviral-delivered boosts, represents a
reasonable strategy to augment, broaden and prolong immune protection against tuberculosis (…

Introduction In the absence of clinical efficacy data, vaccine protective effect can be extrapolated
from animals to humans, using an immunological biomarker in humans that correlates …

Several COVID-19 vaccines have recently gained authorization for emergency use. Limited
knowledge on duration of immunity and efficacy of these vaccines is currently available. …